Patient-specific induced pluripotent stem cell (iPSC)-derived astrocytes and ventral midbrain dopaminergic neurons (vmDAns) from PD patients with LRRK2 mutation and genetically engineered iPSC cell lines using CRISPR/Cas9 technology to tag α-synuclein. This evidence concerns the gene LRRK2 and Parkinson disease.